Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Financial performance
Oncology
Innovation: Pipeline overview
Financial review
Conclusion
Appendix
Innovation: Clinical trials
Reconciliation of IFRS results vs. results excluding gain recognized
on divestment of Roche investment
IFRS
USD million unless indicated otherwise
results
Gain on divestment of
our investment in Roche
Results excl. gain on divestment
of our investment in Roche
Operating income from continuing operations
11,689
Net income
24,018
Total basic earnings per share (USD)
10.71
-14,572
-6.50
11,689
9,446
4.21
Reconciliation from IFRS
reported net income and
basic earnings per share,
to net income and basic
earnings per share
excluding the gain
recognized on the
divestment of our
investment in Roche
2021
Summary of impact of
the gain recognized
on the divestment of
our investment in
Roche in USD and
constant currencies
on net income and
basic earnings per
share
54 Investor Relations | Q4 2021 Results
In USD %
Excluding the gain
on divestment of
our investment
In constant currencies %
Excluding the gain
on divestment of
our investment
in Roche
Percentage
in Roche
2021
%
%
point impact
%
%
Percentage
point impact
Net income
198
17
181
195
15
180
Total basic earnings per share (USD)
202
19
183
200
17
183
1 NOVARTIS | Reimagining MedicineView entire presentation